This page shows the latest cell therapies news and features for those working in and with pharma, biotech and healthcare.
Cell and genetic therapies are key to our strategy of developing transformative therapies for serious diseases, and this agreement is an important next step in cementing our leadership in these modalities ... as we bring forward our broad gene and
Abecma is a CAR T cell therapy approved for pre-treated myeloma patients. ... Samit Hirawat, chief medical officer, BMS said: “CAR T cell therapies have shown transformational potential for the treatment of haematologic malignancies and we, with our
Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients. ... the team at Vertex,” said Bastiano Sanna, executive vice president and chief of cell and genetic therapies at
bluebird bio has posted a modest increase in its Q4 revenues and has also provided an update about its clinical hold on its sickle cell disease gene therapy LentiGlobin. ... BMS) and monetisation for ex-US milestones and royalties from CAR T cell
three CD3-engaging T-cell re-directing bispecific antibody therapies. ... Merus has built a differentiated platform, one that we believe can enable us to create bispecific antibody therapies with wider therapeutic indexes than those available today.
Takeda will also work with KSQ on the discovery and development of natural killer (NK) cell targeted therapies identified through the collaboration. ... Working alongside KSQ will facilitate smart drug discovery and development of what we hope will be
More from news
Approximately 2 fully matching, plus 143 partially matching documents found.
In my opinion, these new pathways will establish themselves and be extended to other treatments, including cell and gene therapies. ... Mike Fraser is General Manager, EMEA at Novartis Gene Therapies. 16th February 2021. .
By Clive Glover. Since the approval of the first five gene or gene-modified cell therapies in the US – Luxturna, Yescarta, Tecartus, Kymriah and Zolgensma – this new technology has been evolving ... must create manufacturing processes for cell and
the first generation of gene and cell therapies. ... Many drug developers also have looked to engage and acquire companies with synergistic discovery-stage platforms to expand their portfolios to include next-generation and potentially curative therapies
This trend is not surprising – in part driven by the pressures facing healthcare budgets through the rising incidence of chronic diseases, as well as the advent of cell and gene therapies ... For novel therapies (including medicines aimed at rare
Thanks to advances in technology and new commercial viability, cell and gene therapy is finally coming of age. ... Another example is Maxcyte, a global cell- based therapies and life sciences company that is developing its CARMA process, where a
More from intelligence
Approximately 0 fully matching, plus 47 partially matching documents found.
An expert in cell and gene therapies, Dr Ferrari joins emotive following 20 years in research as well as holding medical affairs and commercial roles in biopharma and diagnostics. ... It is also charged with developing HCP engagement on gene silencing
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand
Stefano Buono and Richard Van Duyne join the biopharma. Abeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the ... He said: “Abeona’s ambitious
Prior to his new role, he was chief business officer at SQZ Biotech, a clinical-stage group focusing on developing cell therapies.
More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.
For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover. ... New therapies that minimize hospital visits may have to be prioritized by pharmaceuticals and MedTech companies.
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... If you would like to discuss how we could help you deliver outcomes with your advanced therapies then please contact me:.
the cost curve to accommodate new and expensive cell and gene therapies. In addition to this, insurance plans demand lower co-pays for hospital costs i.e. ... can. Potential methods of payment proposed for expensive cell and gene therapies include:.
Gavin Jones is looking forward to sessions on innovation in advanced therapies and working towards equitable access. ... Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.
However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
More from PMHub
Approximately 0 fully matching, plus 15 partially matching documents found.